Realist, the value to an acquiring Pharma from the book losses component of an acquisition would run the same whether the reason for the acquisition becomes number 3 on your list (the targeted company carries shareholder value of interest) or is the sole reason for the acquisition, correct?
$550 million in accumulated operating losses will get whittled down if PPHM begins to show net revenues within the next year or two, reducing the tax value to the acquiring Pharma while increasing the value the Pharma may expect to pay for PPHM. Considering time value of money, a success bound PPHM acquired near term is a bigger carrot for acquisition than waiting for PPHM to see Avid turn their balance sheet positive and for PPHM to find a partner for cancer duagnostics test deployment.
LOL! I will try to find examples of companies acquired for tax value if you can credibly affirm such tax loss value doesn't exist as part of an acquisition negotiated purchase price...
Aren't corporate tax rates targeted for being dropped by the new Administration? That would have the acquisition tax loss value drop, starting the tax year when the change applies. The window of time between PPHM profitability coupled with timing for reduced tax loss value on one end gets bracketed by the February PPHM, research findings announcment of 100% success in the cancer detection proof of concept paper.
Best wishes and IMO.
KT
Market Data 
Markets 
AI
